Pages that link to "Q64990357"
Jump to navigation
Jump to search
The following pages link to State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. (Q64990357):
Displaying 50 items.
- Cost-effectiveness modelling in diagnostic imaging: a stepwise approach (Q26823853) (← links)
- Oncotyrol--Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research. (Q30378973) (← links)
- A systematic review of the quality of economic models comparing thrombosis inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention (Q33413196) (← links)
- Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. (Q33651094) (← links)
- Modeling the Impact of Retention Interventions on Mother-to-Child Transmission of HIV: Results From INSPIRE Studies in Malawi, Nigeria, and Zimbabwe (Q33688086) (← links)
- Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model (Q33836709) (← links)
- BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries (Q34340697) (← links)
- Cost-effectiveness of enhanced syphilis screening among HIV-positive men who have sex with men: a microsimulation model (Q35199101) (← links)
- Modeling the Impact of Alternative Immunization Strategies: Using Matrices as Memory Lanes (Q35824526) (← links)
- Building better models: if we build them, will policy makers use them? Toward integrating modeling into health care decisions (Q35854588) (← links)
- Burden of type 2 diabetes in Mexico: past, current and future prevalence and incidence rates (Q36373206) (← links)
- Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis (Q36400944) (← links)
- Comparative Effectiveness of Biomarkers to Target Cancer Treatment: Modeling Implications for Survival and Costs (Q36614650) (← links)
- Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis (Q36731638) (← links)
- Economic evaluations on centralisation of specialised healthcare services: a systematic review of methods (Q36883740) (← links)
- Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK. (Q37177894) (← links)
- Lives saved by expanding HIV treatment availability in resource-limited settings: the example of Haiti (Q37290659) (← links)
- A Comparison of Agent-Based Models and the Parametric G-Formula for Causal Inference (Q38609868) (← links)
- An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article (Q38672008) (← links)
- Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals (Q38691333) (← links)
- Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: A cost-effectiveness analysis (Q38906326) (← links)
- Economic evaluations with agent-based modelling: an introduction (Q39051954) (← links)
- The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. (Q39137372) (← links)
- Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list (Q39139767) (← links)
- Changing Cycle Lengths in State-Transition Models: Challenges and Solutions (Q39638320) (← links)
- Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada (Q40374202) (← links)
- Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada (Q42201516) (← links)
- Viral hepatitis: Cost-effectiveness of direct-acting antivirals for chronic hepatitis C. (Q42995272) (← links)
- Transplanting HCV-positive livers into HCV-negative patients with preemptive antiviral treatment: A modeling study (Q46626377) (← links)
- Incremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial-Based Cost Data. (Q47308359) (← links)
- Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview. (Q48062582) (← links)
- A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. (Q48118406) (← links)
- Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions (Q48681310) (← links)
- Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers (Q48710370) (← links)
- Microsimulation Modeling for Health Decision Sciences Using R: A Tutorial. (Q52340299) (← links)
- Characterizing Heterogeneity Bias in Cohort-Based Models. (Q53169965) (← links)
- Methods and quality of disease models incorporating more than two sexually transmitted infections: a protocol for a systematic review of the evidence. (Q55139122) (← links)
- Cost-Effectiveness Analyses in Orthopaedic Surgery: Raising the Bar. (Q55524587) (← links)
- The effect of model selection on cost-effectiveness research: a comparison of kidney function-based microsimulation and disease grade-based microsimulation in chronic kidney disease modeling (Q58560760) (← links)
- Congenital heart defect repair with ADAPT tissue engineered pericardium scaffold: An early-stage health economic model (Q58691537) (← links)
- Comparing Strategies for Modeling Competing Risks in Discrete-Event Simulations: A Simulation Study and Illustration in Colorectal Cancer (Q60931942) (← links)
- Psychotherapy for Major Depressive Disorder and Generalized Anxiety Disorder: A Health Technology Assessment (Q61635299) (← links)
- Economic impact of potentially inappropriate prescribing and related adverse events in older people: a cost-utility analysis using Markov models (Q64230334) (← links)
- Is risk-stratified breast cancer screening economically efficient in Germany? (Q64935691) (← links)
- What kind of health economics do we need? (Q87288899) (← links)
- Impact of increasing treatment rates on cost-effectiveness of subcutaneous immunotherapy (SCIT) in respiratory allergy: a decision analytic modelling approach (Q88160543) (← links)
- Discretely Integrated Condition Event Simulation for Pharmacoeconomics (Q88348882) (← links)
- Cost-Effectiveness Analysis of an Adherence-Promotion Intervention for Children With Leukemia: A Markov Model-Based Simulation (Q88712449) (← links)
- Identifying Patients for Whom Lung Cancer Screening Is Preference-Sensitive: A Microsimulation Study (Q88890026) (← links)
- Cost-effectiveness of an in-home respite care program to support informal caregivers of persons with dementia: A model-based analysis (Q89503212) (← links)